- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06676761
Outcomes of a Novel Technique Minimal Scar Mastectomy
November 5, 2024 updated by: KK Women's and Children's Hospital
Nipple sparing mastectomy is oncologically safe and has a good cosmetic outcome.
However, nipple sparing mastectomy was conventionally performed with reconstruction.
Minimal scar mastectomy (MSM) is a novel technique which could allow women, with non-ptotic breasts, who do not want reconstruction, to conserve their nipple areolar complex (NAC) and avoid the transverse scar associated with modified radical mastectomy.
This is the first study on the oncologic and surgical outcomes of MSM.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
100
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Geok hoon Lim
- Phone Number: 96392353
- Email: ghlimsg@yahoo.com.sg
Study Locations
-
-
-
Singapore, Singapore
- Recruiting
- KK Women's and Children's Hospital
-
Contact:
- Geok hoon Lim
- Phone Number: 96392353
- Email: ghlimsg@yahoo.com.sg
-
Singapore, Singapore, 238255
- Recruiting
- KK Women's and Children's Hospital
-
Contact:
- Geok hoon Lim
- Phone Number: 96392353
- Email: ghlimsg@yahoo.com.sg
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
breast cancer patients with non-ptotic breasts, who do not want reconstruction, to conserve their nipple areolar complex (NAC) and avoid the transverse scar associated with modified radical mastectomy.
Description
Inclusion Criteria: breast cancer patients who opted for minimal scar mastectomy -
Exclusion Criteria: breast cancer patients who underwent conventional mastectomy
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
nipple sparing mastectomy without reconstruction
|
nipple sparing mastectomy was conventionally performed with reconstruction.
we aim to study the outcomes in the group of patients with Minimal scar mastectomy (MSM) who have nipple sparing mastectomy without reconstruction
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
oncological outcome
Time Frame: 5 years from operation
|
recurrence rate
|
5 years from operation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Lim GH, Allen JC, Ng RP. Oncoplastic round block technique has comparable operative parameters as standard wide local excision: a matched case-control study. Gland Surg. 2017 Aug;6(4):343-349. doi: 10.21037/gs.2017.03.06.
- Lim GH. How to do minimal scar mastectomy: first-reported novel concept of nipple sparing mastectomy without reconstruction. ANZ J Surg. 2018 Dec;88(12):1345-1346. doi: 10.1111/ans.14941. Epub 2018 Nov 1. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 1, 2017
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
December 31, 2030
Study Registration Dates
First Submitted
November 5, 2024
First Submitted That Met QC Criteria
November 5, 2024
First Posted (Actual)
November 6, 2024
Study Record Updates
Last Update Posted (Actual)
November 6, 2024
Last Update Submitted That Met QC Criteria
November 5, 2024
Last Verified
October 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB 2020/2147
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
will consider sharing IPD when paper was accepted for publication
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer Early Stage Breast Cancer (Stage 1-3)
-
Fudan UniversityNot yet recruitingBreast Cancer Early Stage Breast Cancer (Stage 1-3)China
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruitingBreast Cancer Early Stage Breast Cancer (Stage 1-3) | HR Positive/HER2 Low Breast CancerChina
-
St. Antonius HospitalRijnstate Hospital; Amphia Hospital; Antoni van Leeuwenhoek HospitalNot yet recruitingBreast Cancer Stage I | Breast Cancer Early Stage Breast Cancer (Stage 1-3)Netherlands
-
Pengfei QiuNot yet recruitingBreast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3)China
-
University College London HospitalsUniversity of West LondonRecruitingBreast Cancer Early Stage Breast Cancer (Stage 1-3)United Kingdom
-
West China HospitalWest China Fourth Hospital, Sichuan University; The Fourth People's Hospital...Not yet recruitingBreast Cancer Early Stage Breast Cancer (Stage 1-3)China
-
Casa Sollievo della Sofferenza IRCCSFondazione IRCCS Istituto Nazionale dei Tumori, Milano; Fondazione IRCCS Policlinico... and other collaboratorsEnrolling by invitationBreast Cancer Early Stage Breast Cancer (Stage 1-3)Italy
-
Peking University People's HospitalRecruitingHER2-negative Breast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Hormone Receptor-Positive Breast Cancer | Early-Stage Breast Cancer | ctDNA Monitoring | High-risk Breast CancerChina
-
Nanfang Hospital, Southern Medical UniversityRecruitingBreast Cancer Early Stage Breast Cancer (Stage 1-3)China
-
Fondazione Policlinico Universitario Agostino Gemelli...Clinical Research Technology S.r.l.Not yet recruitingBreast Cancer Early Stage Breast Cancer (Stage 1-3)Italy
Clinical Trials on nipple sparing mastectomy without reconstruction
-
Second Affiliated Hospital, School of Medicine,...Not yet recruitingBreast Cancer | Invasive Breast Carcinoma | Ductal Carcinoma In Situ, DCISChina
-
The First Affiliated Hospital with Nanjing Medical...Not yet recruiting
-
University Hospital, MontpellierRecruiting
-
Severance HospitalSamsung Medical Center; Asan Medical Center; Kyungpook National University Chilgok...Active, not recruitingBreast Neoplasms | Benign Breast Disease | Germline BRCA1 Gene Mutation | Germline BRCA2 Gene Mutation | Germline Mutation AbnormalityKorea, Republic of
-
Changhua Christian HospitalMinistry of Science and Technology, Taiwan; Intuitive SurgicalRecruiting
-
Severance HospitalSamsung Medical Center; Changhua Christian Hospital; European Institute of OncologyCompletedRecurrence | Postoperative Complications | Breast Cancer | Breast Neoplasms | Surgery | Surgery--Complications | BRCA1 Mutation | BRCA2 MutationKorea, Republic of
-
Karolinska University HospitalKarolinska Institutet; LifeCellCompletedBreast CancerSweden, United Kingdom
-
University of MiamiActive, not recruitingBreast Cancer | Ductal CarcinomaUnited States
-
Yonsei UniversityRecruitingBreast Cancer Classified as TNM Stage 0-IIIaSouth Korea
-
Changhua Christian HospitalMinistry of Science and Technology, Taiwan; Intuitive SurgicalUnknownBreast Cancer FemaleTaiwan, Korea, Republic of, Italy